S ubclinical hypothyroidism is a common condition associated with a raised thyroid-stimulating hormone and a normal serum free thyroxine that affects about 10% of females over 55 years in age. The most common cause is autoimmune thyroid disease, with 2.5% of patients with subclinical hypothyroidism progressing to clinically overt hypothyroidism each year. The rate of progression is higher in patients with anti-thyroid peroxidase antibodies and higher levels of thyroid-stimulating hormone. Only a small proportion of patients with subclinical hypothyroidism have symptoms, and although there is some debate in the literature about which patients should be treated, the National Institute for Health and Care Excellence clinical knowledge summaries give clear recommendations. There is an increased risk of cardiovascular disease in patients with subclinical hypothyroidism; it is uncertain whether treatment with levothyroxine reduces this risk. When deciding whether to treat subclinical hypothyroidism consider the patient's age, symptoms, presence of antithyroid peroxidase antibodies, thyroid-stimulating hormone levels and risk factors such as cardiovascular disease.
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The GP curriculum and subclinical hypothyroidism Clinical module 3.17: Care of people with metabolic problems states that a GP should be able to demonstrate an understanding: . Of how common endocrine or metabolic disorders such as diabetes mellitus, thyroid or reproductive disorders can present . That biomedical tests can be diagnostic and often necessary for monitoring metabolic and endocrine diseases, so it is important for GPs to know which tests are useful in a primary care setting and how to interpret these tests and understand their limitations
Definition
Subclinical hypothyroidism (SCH) is defined by an elevated level of thyroid-stimulating hormone (TSH) but normal serum free thyroxine (T4) and triiodothyronine (T3) concentrations. Clinical symptoms are usually absent, but in patients with TSH levels above 10 mIU/L symptoms are more often present (National Institute for Health and Care Excellence (NICE), 2018; Peeters, 2017).
Epidemiology
SCH is common with a prevalence of approximately 3-8%. Prevalence typically increases with age and it is more common in women (Fatourechi, 2009; Lowth, 2014; McCarthy et al., 2016) . For male and female patients in their sixties, the prevalence is similar with a combined prevalence of 10% (Fatourechi, 2009) . Anti-thyroid antibodies are detected in approximately 80% of patients with SCH (Fatourechi, 2009 ).
Aetiology
The most common cause is autoimmune thyroid disease; however, previous radioiodine therapy, thyroid surgery and external radiation therapy can also result in SCH (Fatourechi, 2009 ).
Subclinical hypothyroidism and association with other diseases

Cardiovascular disease
There is a known link between cardiovascular disease (CVD) and SCH (Adamarczuk-Janczyszyn et al., 2016; Carbotta et al., 2017; Delitala et al., 2017; Fatourechi, 2009; Redford and Vaidya, 2017; Rodondi et al., 2010; Tng, 2016; Tseng et al., 2012) . A meta-analysis of individual participant data from 11 prospective cohort studies with 55 000 participants demonstrated that the risk of fatal and nonfatal events of coronary heart disease increased with higher levels of TSH, particularly those greater than 10 mIU/L (Rodondi et al., 2010) . Another cohort study of 115 746 participants demonstrated that adult Taiwanese patients with SCH had an increased risk for allcause mortality and CVD death (Tseng et al., 2012) . Multiple observational studies have demonstrated a significant association between SCH and CVD, however, data is lacking from randomised control trials for the treatment of SCH with levothyroxine and the effect on the long-term clinical outcomes of cardiovascular disease (Peeters, 2017) .
Dyslipidaemia
There have been other studies that have looked specifically at the relationship between increased levels of TSH and dyslipidaemia (Biondi and Cooper, 2008) . One study compared obese women aged 50 to 70 years: 100 women with SCH, 45 with overt hypothyroidism and 42 with normal levels of TSH (AdamarczukJanczyszyn et al., 2016) . Total cholesterol, low-density lipoprotein (LDL)-cholesterol and triglyceride concentrations were higher in the SCH group compared with controls, and these decreased after treatment with levothyroxine. Furthermore, both systolic and diastolic blood pressure decreased significantly after treatment. Other studies also support the benefit of improving lipid profiles in patients with SCH treated with levothyroxine (Zhao et al., 2016) . Another study found that in SCH female patients with positive thyroid peroxidase antibody (TPOAb) tests, their total cholesterol, LDL cholesterol and triglycerides were significantly raised (Srivastava and Singh, 2017) .
Nonalcoholic fatty liver disease
One study demonstrated that in patients with significant SCH (TSH levels greater than 10 mIU/L) and those with mild SCH (TSH levels 4.2-10 mIU/L) with dyslipidaemia, who received thyroxine replacement, experienced decreases in the prevalence of non-alcoholic fatty liver disease (NAFLD) and serum alanine aminotransferase (ALT) levels. This suggests that in SCH patients with NAFLD, appropriate treatment with levothyroxine may improve their NAFLD (Liu et al., 2017) .
Clinical features
For patients diagnosed with SCH, their symptoms are usually milder than patients with overt hypothyroidism and tend to increase in both number and severity with increasing levels of TSH (Peeters, 2017 (NICE, 2018) . NICE also recommend checking the TPOAb level if autoimmune thyroid disease is suspected. The European Thyroid Association (ETA)'s guideline on the management of SCH considers TPOAb to be the most sensitive serological test for thyroid autoimmunity in SCH (Pearce, 2013) . The ETA recommends that patients with a raised serum TSH and FT4 within the reference range should undergo TPOAb testing in addition to repeat TSH and FT4, after a 2-to 3-month interval. Repeat testing of TPOAb is not recommended and does not enhance the monitoring of patients with SCH. A neck ultrasound scan is not routinely recommended.
When to treat with levothyroxine?
Many patients with SCH do not need treatment. NICE treatment recommendations are based on the TSH test result and characteristics of the patients and are summarised in Box 3.
Levothyroxine initiation and titration
For most people 50-100 micrograms of levothyroxine once daily is an appropriate starting dose. This should be adjusted in increments of 25-50 micrograms every 3 to 4 weeks, based on clinical response. The usual maintenance dose is 100-200 micrograms once daily. For people over 50 years in age and people with cardiac disease or severe hypothyroidism, the recommendation is 25 micrograms once daily, adjusted in increments of 25 micrograms every 4 weeks, based on clinical response. After initiation, or a change in levothyroxine dose, the TSH level should be checked within 6-8 weeks (Chakera et al., 2012) . Clinicians should aim for an appropriate dose of levothyroxine to maintain a stable TSH level in the lower half of the reference range (0.4-2.5 mIU/L). Once this is achieved, check the level of TSH at 4-6 months and annually thereafter. Advise patients to take levothyroxine at least 30 minutes before breakfast, caffeine-containing liquids such as tea or coffee and any other drugs. The NICE CKS guidelines outline contraindications and cautions, adverse effects and drug interactions which can be located easily online (NICE, 2018) . Box 4 outlines when to refer or discuss a patient with SCH.
Prognosis
Without treatment, 37% of people with SCH may revert spontaneously back to normal (LeFevre, 2015) . Approximately 2-5% of people with SCH develop overt hypothyroidism and this is more likely with higher levels of TSH (greater than 10 mIU/L) and positive TPOAb test (LeFevre, 2015) . The annual rate of progression for patients with both anti-thyroid InnovAiT antibodies and raised TSH is 4%, and for raised TSH alone 2-4%. In patients with anti-thyroid antibodies alone, 1-3% progress to overt hypothyroidism (Cooper and Biondi, 2012) .
Case study 1.
A Caucasian female in her sixties with a 10-month history of abdominal bloating that is worse after eating wheat, but without any change in bowel habit, dysphagia or vomiting, presents at a routine appointment. Weight is unchanged and abdominal examination is normal. Blood tests (full blood count, thyroid function tests, Ca125, coeliac screen) and an urgent ultrasound scan of the abdomen and pelvis are requested.
The blood tests are normal except for abnormal results from the thyroid function tests. The ultrasound shows gallstones and fatty liver changes, but is otherwise normal. The patient subsequently has a laparoscopic cholecystectomy.
The thyroid function tests reveal a TSH level of 19.4 mIU/L (0.20-4.00) and a T4 level of 11.0 pmol/L (10.0-20.0 pmol/L). At follow up, the patient reports a 2-year history of low energy, tiredness, feeling the cold and low libido. Her weight has remained stable with a normal bowel habit and a menopause at age 50 years. There is a family history of laryngeal cancer affecting her mother who also takes levothyroxine following a partial thyroidectomy. There is no family history of any autoimmune disease.
On examination, blood pressure is 198/96 mmHg, pulse is regular at 73 beats per minute and body mass index of 29.1 kg/m 2 . Visual acuity, fundoscopy and neck examination are normal with no goitre or cervical lymphadenopathy.
Amlodipine is prescribed for blood pressure. Repeat thyroid function tests, including TPOAb urea and electrolytes, liver function tests, full lipid profile and haemoglobin A1c are requested.
Results reveal a TSH level of 33 mIU/L (0.20-4.00 mIU/ L), a T4 level of 10.4 pmol/L (10.0-20.0 pmol/L) and TPOAb level of 582 iu/mL(<100 iu/mL). The total cholesterol is 5.7 mmol/L, with normal results obtained in urea and electrolytes and liver function tests.
Levothyroxine 25 micrograms once a day is started. Amlodipine is further increased to 10 mg once a day as the repeat blood pressure was 148/74 mmHg. Her QRISK2 cardiovascular disease 10-year risk score is calculated to be 8.97% and a statin is not therefore indicated.
Cholesterol levels may be elevated in hypothyroidism and decrease with levothyroxine treatment; coexistent hypothyroidism and statin therapy may increase the risk of myopathy and rhabdomyolysis.
Six weeks after initial treatment the TSH level has reduced to 13.1 mIU/L and the T4 level is 12.7 pmol/L. The dose of levothyroxine is increased to 50 micrograms daily and repeat thyroid function tests planned 6 weeks later. Her repeat blood pressure was 126/74 mmHg and Amlodpine 10 mg daily is continued.
KEY POINTS
. SCH is a common condition . SCH is defined as a raised level of TSH and normal levels of T4 and T3, clinical symptoms are usually absent, however, in patients with TSH level above 10 mIU/L symptoms are more often present InnovAiT
